The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.30
Bid: 3.20
Ask: 3.40
Change: 0.05 (1.54%)
Spread: 0.20 (6.25%)
Open: 3.25
High: 3.30
Low: 3.10
Prev. Close: 3.25
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Frasers invests in MySale; Kefi keeps license

Thu, 30th Jun 2022 11:35

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

----------

AIM - WINNERS

----------

Kefi Gold & Copper PLC, up 44% at 0.71 pence, 12-month range 0.42p-2.10p. The miner says it has been informed by the Ethiopian government that the Tulu Kapi license has not been cancelled. The Ethiopian Minister of Mines told the company that recent media reports of license cancellation were inaccurate, and confirmed that the regulator's review will continue to ensure the earliest possible launch of the gold project. In addition, KEFI says it has signed an umbrella agreement with the project's finance syndicate, setting out a full funding package.

----------

MySale Group PLC, up 28% at 1.59p, 12-month range 1.03p-8.95p. Mike Ashley's Frasers Group PLC acquires a 28.7% holding in the Australian-based fashion marketplace. Frasers says this creates an opportunity for a strategic partnership whereby end of line products can be cleared via an established clearance channel. This pipeline will be enhanced by the benefits of counter seasonality between the European and Australian climates, the FTSE 250 company adds. Frasers is down 1.9%.

----------

AIM - LOSERS

----------

Cornerstone FS PLC, down 44% at 10.70p, 12-month range 8.15p-42.5p. The cloud-based payment services provider posts widened pretax loss in 2021 of GBP4.2 million from GBP2.2 million in 2020 on revenue that rises 38% to GBP2.3 million from GBP1.7 million. Cornerstone also says Non-Executive Chair Elliott Mannis is stepping down from August for personal reasons. He will be replaced by Non-Executive Director Gareth Edwards.

----------

ValiRx PLC, down 34% at 10.80p, 12-month range 10.34p-63.00p. The drug development company plans to raise GBP1.5 million through a discounted placing. The proceeds will be used for working capital to continue development of its assets and to strengthen the balance sheet with a view to potential acquisitions. ValiRx will place 15 million shares at 10.00p a share, a discount of 38% to 16.25p closing share price on Wednesday.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
24 Jul 2020 17:23

IN BRIEF: ValiRx Raises GBP300,700 From Broker Option

IN BRIEF: ValiRx Raises GBP300,700 From Broker Option

Read more
23 Jul 2020 18:02

UK TRADING UPDATE SUMMARY: Gear4music Strikes Right Note As Sales Jump

UK TRADING UPDATE SUMMARY: Gear4music Strikes Right Note As Sales Jump

Read more
16 Jul 2020 15:57

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
6 Jul 2020 18:19

IN BRIEF: ValiRx Outlines Oncology, Women's Health Focus

IN BRIEF: ValiRx Outlines Oncology, Women's Health Focus

Read more
6 Jul 2020 09:31

ValiRx looks to build on portfolio of drug candidates

(Sharecast News) - Medicines developer ValiRx said on Monday that it was looking to build on its existing portfolio of drug candidates and grow a pipeline of innovative, early-stage projects in the areas of oncology and women's health.

Read more
1 Jul 2020 13:10

IN BRIEF: ValiRx Annual Loss Narrows As Expenses Fall

IN BRIEF: ValiRx Annual Loss Narrows As Expenses Fall

Read more
16 Jun 2020 13:58

IN BRIEF: ValiRx Cuts Pay By Two Thirds; Terminates GeneICE Agreement

IN BRIEF: ValiRx Cuts Pay By Two Thirds; Terminates GeneICE Agreement

Read more
8 Jun 2020 15:39

ValiRx Delays Annual Results Amid Covid-19 Pandemic

ValiRx Delays Annual Results Amid Covid-19 Pandemic

Read more
2 Jun 2020 12:57

UK TRADING UPDATE SUMMARY: Novacyt Virus Test Orders At EUR135 Million

UK TRADING UPDATE SUMMARY: Novacyt Virus Test Orders At EUR135 Million

Read more
2 Jun 2020 12:03

ValiRx enters collaboration agreement for Covid-19 treatment

(Sharecast News) - Biotechnology oncology company ValiRx has entered into a collaboration agreement with Oncolytika and Black Cat Bio to explore the use of VAL201 in a combination treatment for patients suffering a hyperimmune response to Covid-19.

Read more
29 May 2020 15:02

UK TRADING UPDATE SUMMARY: Catenae Inks Pilot Pact For Cov-ID App

UK TRADING UPDATE SUMMARY: Catenae Inks Pilot Pact For Cov-ID App

Read more
29 May 2020 12:59

ValiRx offloads non-core IP to DDTech

(Sharecast News) - ValiRx has entered into a deed of assignment with Drug Discovery Technologies (DDTech) for the patents, materials and know-how associated with its non-core intellectual property 'FitBio' and 'TRAC', it announced on Friday.

Read more
27 May 2020 14:20

UK EXECUTIVE CHANGE SUMMARY: ValiRx Appoints Biotaspheric CEO As Chair

UK EXECUTIVE CHANGE SUMMARY: ValiRx Appoints Biotaspheric CEO As Chair

Read more
7 May 2020 14:45

UK EXECUTIVE CHANGE SUMMARY: Connect Picks Ex-Synthomer CFO As Chair

UK EXECUTIVE CHANGE SUMMARY: Connect Picks Ex-Synthomer CFO As Chair

Read more
4 May 2020 16:18

REPEAT: ValiRx Completes GBP1.2 Million Placing For Trial Close-Out

REPEAT: ValiRx Completes GBP1.2 Million Placing For Trial Close-Out

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.